Valganciclovir Hydrochloride Syrup Suppliers & Bulk Manufacturers

Available Forms: Oral Syrup

Available Strengths: 25 mg/mL

Reference Brands: Generic formulations marketed under different names

Category: Nephrology

Valganciclovir Hydrochloride Tablets are antiviral medications used to prevent and treat cytomegalovirus (CMV) infections, especially in kidney transplant patients.it helps reduce the risk of CMV infection in immunocompromised patients. Valganciclovir Hydrochloride Syrup is available in Oral Syrup and strengths such as 25 mg/mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Valganciclovir Hydrochloride Syrup is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Valganciclovir Hydrochloride Syrup can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Valganciclovir is an antiviral medication used to prevent and treat cytomegalovirus (CMV) infections, particularly in immunocompromised patients such as those with HIV/AIDS or individuals who have undergone organ transplants. Marketed under the brand name Valcyte and other regional brands, valganciclovir works by inhibiting viral DNA replication, thereby controlling the growth and spread of CMV. It is available in oral formulations, including tablets and oral solutions, which allow for flexible dosing for adults, children, and patients who have difficulty swallowing.

Valganciclovir does not cure CMV infection but helps suppress viral activity, making it an important long-term therapy for at-risk patients. The medication is typically taken orally under medical supervision, with dosing adjusted according to kidney function and patient weight. Oral administration ensures steady absorption and effective antiviral activity, supporting both prophylaxis and treatment of active infections. Valganciclovir has become a key component in managing CMV-related complications in immunocompromised populations, improving patient outcomes and reducing the risk of serious viral disease.